New anti-VEGF shows good results in poor responders to previous anti-VEGF therapy

COPENHAGEN, Denmark — Preliminary 8-month experience with aflibercept shows remarkable improvement in cases that responded poorly to previous continuous, extensive therapy with bevacizumab or ranibizumab, according to one specialist."In our clinic, we have an average volume of 7,000 intravitreal injections per year, and in the last 8 months, about 1,000 were aflibercept," Stephan Michels, MD, head of Medical Retina at Triemli Hospital in Zurich, Switzerland, said at the meeting of the European Society of Ophthalmology.

Full Story →